Personalized & regenerative medicine

01Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Personalized and regenerative medicine delivers durable, often one-time treatments by correcting or replacing disease-causing genetic defects at the cellular level. Four approved product classes now coexist: AAV gene replacement (Zolgensma $2.125M for SMA, Elevidys $3.2M for DMD), lentiviral HSC gene addition (Libmeldy, Strimvelis), ex vivo CRISPR editing of autologous stem cells (Casgevy $2.2M for sickle cell / beta-thal), and in vivo CRISPR via lipid nanoparticle delivery (Intellia lonvo-z Phase 3 positive in HAE, rolling BLA 2026). The global ATMPs market exceeded $5B in 2025 and is projected to reach $25B by 2030 at >30% CAGR. Manufacturing remains the dominant bottleneck: AAV vector production requires specialised cGMP bioreactor suites; ex vivo CRISPR requires patient-specific manufacturing windows of 4–8 weeks.

The key platforms of personalized & regenerative medicine are:

1. AAV Gene Replacement (AAV Gene Therapy): single-stranded recombinant AAV vectors (serotypes rh74, AAV9) deliver a functional gene copy; one administration produces durable expression >3 years in SMA and DMD clinical data.
2. Lentiviral HSC Gene Addition (Lentiviral Gene Therapy): ex vivo transduction of autologous haematopoietic stem cells; approved for ADA-SCID, MLD (OTL-200/Libmeldy) and X-ALD.
3. Ex vivo CRISPR editing (CRISPR/Cas9 HSC): Cas9 knocks out BCL11A in autologous HSCs to reactivate foetal haemoglobin — basis of Casgevy (exa-cel), first CRISPR medicine approved by FDA (Dec 2023) and EMA.
4. In vivo CRISPR via LNP (LNP-CRISPR): ionisable LNPs deliver Cas9 mRNA + sgRNA to hepatocytes; Intellia lonvo-z achieves >95% TTR knockdown in HAE (Phase 3 HAELO, 2026); clinical proof of concept for redosing demonstrated.

Sectoral value chain

[patient biopsy / HSC harvest] ──> [vector mfg / cell engineering]
                                           │
                              (QC release, cGMP batch)
                                           │
                                           ▼
[patient] <─── [infusion / in vivo dosing] <─── [hospital treatment centre]

Value chain levels

Cross-cutting technologies of the sector:

• Lipid nanoparticles (LNP delivery): ionisable LNP enables in vivo hepatic delivery of mRNA/RNP; critical for in vivo CRISPR and personalised mRNA therapeutics.
• Base editing / prime editing: precise single-nucleotide changes without DSB — next wave after Cas9; Beam Therapeutics and Prime Medicine advancing clinically.
• Cell process automation: closed automated systems (CliniMACS Prodigy, Lonza Cocoon) reduce manual steps and enable decentralised manufacturing.

02US

The US leads globally with >15 approved ATMPs and the largest clinical-stage pipeline; FDA issued Breakthrough and RMAT designations for >40 gene therapy programs in 2025 alone.

AAV approvals, CRISPR first approvals, RMAT pipeline

• Sarepta / Elevidys: FDA expanded Elevidys (delandistrogene moxeparvovec-rokl, AAV rh74) to all ambulatory and non-ambulatory DMD patients ≥4 years; 3-year EMBARK data shows sustained slowing of disease progression.
• CRISPR Therapeutics + Vertex / Casgevy: first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026.
• Intellia / lonvo-z: Phase 3 HAELO data published New England Journal of Medicine (June 2026), rolling BLA submitted; US launch anticipated H1 2027 — first in vivo CRISPR therapy approaching approval.

03CN

China is building a domestic gene therapy industry under NMPA’s accelerated ATMP pathway, with EdiGene and domestic CDMOs advancing CRISPR and viral vector programs.

NMPA ATMP pathway, domestic CRISPR, viral vector CDMOs

• EdiGene (博雅辑因): leading Chinese CRISPR gene editing company; ET-01 (base editing for beta-thalassaemia) in IND-enabling; CRISPR HSC programs under NMPA Fast Track.
• Domestic vector CDMOs: WuXi Advanced Therapies, SinoGene providing AAV and lentiviral vector manufacturing for Chinese and global sponsors.
• NMPA ATMP accelerated pathway: special approval category for innovative gene and cell therapies; priority review timeline 6–9 months for breakthrough designation.

04EU

Europe leads in lentiviral HSC gene therapy approvals (Libmeldy, Strimvelis, Skysona) and in allogeneic CAR-T development; ATMP regulation under EMA’s CAT committee is the gold standard globally.

EMA ATMP approvals, allogeneic CAR-T, Innovation Passport

• Orchard Therapeutics (Kyowa Kirin): OTL-200/Libmeldy EMA-approved for MLD; OTL-203 (MPS-I Hurler) completed registrational enrolment 1 year ahead of schedule; OTL-201 (MPS-IIIA) awarded Innovation Passport (UK ILAP) April 2026.
• Novartis / Itvisma: positive CHMP opinion April 2026 for intrathecal onasemnogene abeparvovec for SMA patients ≥2 years — extends Zolgensma reach to older/heavier patients.
• Cellectis / lasme-cel: FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally.

05Leading companies and research institutes

06Tech stack and innovations

The stack spans viral vector manufacturing, precision gene editing, and LNP delivery — each addressing a distinct disease class and manufacturing model.

1. AAV gene replacement (AAV9 / rh74):
   • single-stranded recombinant AAV; serotype determines tissue tropism (AAV9 — CNS/muscle, rh74 — muscle); produced in HEK293 triple-transfection or baculovirus/Sf9.
   • Zolgensma maintains motor-function improvements >5 years post single IV dose in SMA Type 1.
2. Ex vivo CRISPR/Cas9 (HSC editing):
   • patient HSCs mobilised, collected, edited (electroporation of Cas9 RNP), expanded, reinfused after myeloablative conditioning.
   • Casgevy: BCL11A enhancer knockout reactivates HbF >30%; >95% of SCD/TDT patients free from severe VOCs or transfusions at 24 months.
3. In vivo LNP-CRISPR (hepatic delivery):
   • ionisable LNPs (~80 nm) deliver Cas9 mRNA + sgRNA after IV infusion; liver tropism enables knockdown of secreted disease proteins.
   • lonvo-z: >95% median TTR reduction in ATTR amyloidosis; redosing proof of concept demonstrated; HAELO Phase 3 showed >90% reduction in HAE attacks vs placebo.

07Value chains and production pipelines

Gene therapy manufacturing pipeline (ATMP / cGMP ISO 13485)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Plasmid / vector prep  │ ───> │ 2. Upstream manufacturing │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Cell engineering (ex v)│ <─── │ 3. Downstream purification│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. QC release & fill-fin. │ ───> │ 6. Clinical administration│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Plasmid and vector preparation

GMP plasmid DNA production (transfer vector, packaging plasmid, envelope plasmid) in E. coli fermentation at 10–200 L scale; or AAV ITR-flanked transfer plasmid; endotoxin <0.25 EU/mL specification.

Stage 2: Upstream manufacturing

HEK293 triple-transfection in 50–200 L stirred-tank bioreactor (AAV) or lentiviral packaging; Baculovirus/Sf9 platform for large-scale AAV; cell density 2–5 × 10⁶ cells/mL, harvest at 72–96 h post-transfection.

Stage 3: Downstream purification

Iodixanol / CsCl ultracentrifugation or AEX + SEC chromatography for AAV; TFF + AEX for lentiviral; target: >1 × 10¹³ vg/mL, full/empty capsid ratio >90%, residual DNA <10 ng/dose.

Stage 4: Cell engineering (ex vivo route)

Patient HSC mobilisation (G-CSF + plerixafor), apheresis, CD34+ selection, electroporation of Cas9 RNP or lentiviral transduction; expansion 14–21 days; cell viability >80%, transduction efficiency >70%.

Stage 5: QC release and fill-finish

Potency assay (genome titre by ddPCR, transduction efficiency, HbF induction for Casgevy); sterility; identity (VCN, editing efficiency); replication-competent virus (RCV) testing; batch release 4–8 weeks; fill into cryobags or vials.

Stage 6: Clinical administration

Conditioning chemotherapy (busulfan myeloablation for HSC products); IV infusion or intrathecal injection (Itvisma); 2+ years safety follow-up per FDA/EMA requirement; patient outcome measured by disease biomarkers (VOCs, motor function scores, TTR levels).